Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Portal, Alix; Pernot, Simon; Tougeron, David; Arbaud, Claire; Thirot Bidault, Anne; de la Fouchardière, Christelle; Hammel, Pascal; Lecomte, Thierry; Dréanic, Johann; Coriat, Romain; Bachet, Jean‐Baptiste; Dubreuil, Olivier; Marthey, Lysiane; Dahan, Laëtitia; Tchoundjeu, Bélinda; Locher, Christophe; Lepère, Céline; Bonnetain, Franck; Taı̈eb, Julien

doi:10.1038/bjc.2015.328

Public

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Published in British Journal of Cancer • Sep 1, 2015

Authors:

Alix Portal

Simon Pernot

David Tougeron

Abstract

BACKGROUND: There is currently no standard second-line treatment for metastatic pancreatic adenocarcinoma (MPA), and progression-free survival is consistently <4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of Nab-paclitaxel plus gemcitabine (A+G) after...

Subject

Medicine

FOLFIRINOX

Gemcitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!